Reeves on UK-US deal on drug pricing which is reported to cost an extra GBP3bln/year: "That was part of the agreement in the Spending Review that... would be absorbed. The costs are actually quite low in the first couple of years... But obviously at future spending obviously, everything in the next spending review will be set out in the next spending review.
Find more articles and bullets on these widgets:

RXG6 128 puts paper paid 52 on 8K vs. RXZ5 128.00 puts at 6.5, rolling out the curve.